Latest news with #medicalsolutions
Zawya
2 days ago
- Business
- Zawya
Ateco Pharma Egypt Pharmaceuticals participates in Africa Health ExCon
Eng. Wahid Ateek: Ateco Pharma Egypt Pharmaceutical Products Are Present in 13 Countries... We Aim to reach 15 Markets by 2026 Eng. Wahid Ateek: We Appreciate the State and Political Leadership's Plans to Increase Egyptian Exports to Various Markets Egypt Has Strong Industrial Capabilities... Five Factors Contributing to the Growth of the Medical Sector's Industry and Exports Cairo: As part of its efforts to strengthen its presence and increase exports to African and Arab markets, and in line with the political leadership's directives to increase export rates, Ateco Pharma Egypt, a leading pharmaceutical company in the field of medical solutions manufacturing, participated in Africa Health ExCon, which ran from June 25 to 27, 2025, with wide participation from local and international companies specializing in various medical sectors. Engineer Wahid Ateek, CEO of ATECO Pharma Egypt, confirmed that the company is participating in the exhibition as the first and largest pharmaceutical manufacturer in the Suez Canal Economic Zone, specifically in intravenous solutions. This is done through its presence as one of the Suez Canal Economic Zone's pharmaceutical companies. He added that ATECO's presence at this vital exhibition comes within the framework of its expansion plans to open new markets. ATECO currently exports its products to approximately 13 commercial markets, including Arab, African, and American countries. He said, "We aim to increase this number to more than 15 countries by 2026. This is through an ambitious plan based on the growing demand for our intravenous solutions, as a result of the widespread reputation of the ATECO brand among customers in Egypt and abroad, which reflects the high quality the company has maintained over its years of presence in the market." Ateek continued, "Our main goal is to increase the company's exports of various types and sizes of medical solutions to... The countries most in need and consuming this strategic pharmaceutical product, which bears the "Made in Egypt" label, are working to provide these markets with a safe, high-quality medical product. He added that the company is continuing its expansion of the second and third production lines at its Ain Sokhna plant, and that production capacity is expected to more than double by the beginning of 2026 to meet the growing demand for its high-quality, competitively priced products. He praised the role played by the General Authority for the Suez Canal Economic Zone, with its various departments, in overcoming obstacles and providing the necessary facilities for investors in the region. Ateek added, "Through the Africa Health ExCon exhibition, we seek to introduce our advanced medical solutions products and build strategic partnerships with new suppliers and agents in Africa and the Arab region, supporting our export plans and strengthening Egypt's position as a regional center for the pharmaceutical industry." He said that during the exhibition, he received a large number of visitors and customers from promotional missions and those interested in the medical industry. He continued, "This strategy is in line with the Egyptian state's plan and the directives of the political leadership, headed by President Abdel Fattah El-Sisi, to increase Egyptian exports of various industrial products." Ateek emphasized that Egypt possesses strong industrial capabilities that qualify it to lead the pharmaceutical and medical supplies industry in the region in general. He also emphasized that "Egyptian intravenous solutions of various types have become among the most sought-after medical products in African markets, enjoying great confidence due to their high quality." He pointed out that there are approximately five main factors contributing to the growth of this industry and the increase in its exports during the current phase. Ateek emphasized that among these factors is the significant support provided by the political leadership to the medical sector, by removing obstacles crippling investors, and implementing a clear strategy to maximize Egyptian exports, especially in the medical and pharmaceutical sectors. He continued by saying that Egypt enjoys a stable and secure investment environment, especially in light of the turbulent regional events, making it a destination for foreign investment in the pharmaceutical industry. He also pointed out that among the other components is Egypt's distinguished industrial infrastructure, relying on the latest technologies and including highly qualified and trained human resources, which makes our products competitive in regional and international markets. He also pointed out that Egyptian medical products enjoy several key advantages, including high quality that meets international standards, competitive prices that attract target markets, and a good reputation they have acquired over the years. Ateek did not overlook the importance of Egypt's geographical location as a natural bridge for exporting our medical products to African and Arab markets, especially with the presence of preferential trade agreements with COMESA countries and the League of Arab States that provide customs and tax exemptions," Ateek noted. Engineer Wahid Ateek concluded his remarks by emphasizing that "the Suez Canal Economic Zone will play a pivotal role in boosting Egyptian exports of medical products, with a focus on promising African markets. This is part of a strategy to enhance Egypt's position as a regional hub for the pharmaceutical industry by attracting more foreign and local investments.
Al Bawaba
22-05-2025
- Business
- Al Bawaba
Borouge And Mubadala Bio Sign Partnership Agreement To Strengthen The UAE's Healthcare And Life Sciences Sectors
Borouge, a leading petrochemicals company, that provides innovative and differentiated polyolefins solutions, has signed a strategic cooperation agreement with Mubadala Bio, a life sciences company dedicated to pursuing better health outcomes for the UAE and beyond. The partnership will explore the supply of polyolefin materials to enable local manufacturing of medical products, reinforcing local manufacturing capabilities while contributing to the future of the UAE's healthcare and life sciences sectors. The signing ceremony was witnessed by His Excellency Dr Sultan Al Jaber, UAE Minister of Industry and Advanced Technology and ADNOC Managing Director and Group CEO, Dr. Bakheet Al Katheeri, CEO UAE investments Mubadala, and Ismail Ali Abdulla, Executive Director of UAE Clusters, Mubadala. Hazeem Sultan Al Suwaidi, CEO of Borouge, and Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, signed the agreement during Make it in the Emirates, a flagship UAE event that unites industry leaders to drive innovation and industrial growth. Hazeem Sultan Al Suwaidi, CEO of Borouge, said, 'We are delighted to partner with Mubadala Bio to explore the development of essential medical solutions made at our Ruwais facility in the UAE. Aligned with the ambitions of 'Make it in the Emirates', this collaboration goes beyond the supply of materials, it is about combining the UAE's scientific product innovation with regional insight to bring smarter, safer products for patients and clinicians across the Middle East and beyond.' Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, added, 'This collaboration agreement with Borouge reflects Mubadala Bio's commitment to enabling a world-class, sustainable life sciences sector anchored in advanced local manufacturing. By collaborating with local partners, we aim to grow the manufacturing of UAE-made products. We are strengthening the life sciences sector, supporting the UAE's vision, and enhancing the delivery of essential health products for communities locally and abroad.' Powered by Borealis' Borstar® technology, Bormed™ RG868MO, produced by Borouge in the UAE, marks a key milestone as the initial product offering in Borouge's wider healthcare portfolio. BormedTM RG868MO provides transparency and mechanical strength, and meets industry sterilisation standards, making it ideal for pharmaceutical packaging and medical devices like three-part syringes, inhalers, pharmaceutical caps and closures. The product is already in production at Borouge's manufacturing plant in Al Ruwais Industrial City, Abu Dhabi, representing the first time it has been made for healthcare applications in the UAE. Borouge is set to launch its second healthcare product by the end of the year, building on the momentum of its current Middle East rollout. Aligned with Borouge's commitment to sustainability and innovation, this healthcare solution enables customers to reduce production cycle times through faster processing and can provide an estimated carbon footprint reduction of 5 - 10%. Mubadala Bio officially launched this week at the 'Make it in the Emirates' event, marking a major milestone in the UAE's journey to strengthen its life sciences sector. The new platform brings together integrated biopharma and pharma logistics capabilities to form a vertically integrated company, with a mission to enhance drug security and expand access to affordable, essential treatments. Mubadala Bio's integrated portfolio includes 10 facilities across Asia, Africa and Europe (6 are within the UAE), serving 100+ countries. Through its assets the company has a cumulative manufacturing capacity of 2.5 billion tablets and capsules, and 120 million IVs and injectables annually enabling the production and distribution of more than 10,000 different products.
